Tvax Biomedical

To date, TVAX’s approach to cancer immunotherapy has generated extensive preclinical and clinical data demonstrating efficacy against a wide variety of cancer types while at the same time producing very little toxicity compared to other cancer treatment strategies.

TVAX Immunotherapy Patient Journey Watch this video to learn what to expect during treatment.

TVAX is working to strengthen the immune system’s ability to attack cancer. The page says the immune system eliminates foreign pathogens but does not recognize cancerous threats that arise within the body.

TVAX Biomedical is a clinical-stage development company advancing its proprietary T-cell-based immunotherapy.

TVAX Biomedical is a cancer immunotherapy company advancing to a pivotal glioblastoma study. In September 2022, it received an approximately $2 million, four-year FDA grant for the planned study.

Olathe, KS, March 11, 2019 – TVAX Biomedical, a clinical stage development company advancing its proprietary T cell-based immunotherapy for the treatment of cancer, today announced the decision of the board to hire Dr. Wayne Carter as president and chief executive officer effective immediately.

TVAX Biomedical, Inc. is an Equal Employment Opportunity employer. All qualified candidates will receive consideration for employment without regard to age, race, creed, color, national origin, ancestry, marital status, sex, or sexual orientation.

TVAX Biomedical is a clinical stage development company advancing its novel targeted cell-based immunotherapy for the treatment of cancer.

TVAX Biomedical, Inc. PO Box 19311 Lenexa, KS 66285-9311

Adoptive cell therapy for the treatment of patients with metastatic melanoma. Rosenberg SA, Dudley ME, Curr Opin Immunol. 2009 Apr;21(2):233-40. Epub 2009 Mar 21

TVAX Biomedical, Inc.’s privacy policy explains its data collection and use practices for its website, which is owned or operated by TVAX or companies related by common ownership or control.

TVAX Biomedical’s privacy policy addresses the protection of personal and confidential information from users of its online services and website.